Views & Analysis

Views & Analysis
Industry-Pulse-feature-28_08_2019

Who could replace Sir Andrew Dillon at NICE?

With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements for the man who is arguably the most influential figure in health

Views & Analysis
legalisation medical cannabis

Addressing the medical cannabis knowledge gap

The legalisation of medical cannabis in November 2018 was hailed as a landmark victory for the British medical industry, with scientists, researchers and patients alike all welcoming the ch

Views & Analysis
Almirall looks for action in eczema

Almirall gets in on the eczema action

Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall wants a piece of the action.

Views & Analysis
Who will pay the price for inaction on superbugs

Who will pay the price for inaction on superbugs?

While the UK government has been applauded for its efforts in raising awareness about antimicrobial resistance, its efforts to convince pharma to invest in new antibiotics have so far been